AUSTIN, Texas, April 26, 2018 (GLOBE NEWSWIRE) -- ASPiRA LABs, a Vermillion company (NASDAQ:VRML), today announced that two top physician educational resources, UpToDate and the National Continuing Medical Education (CME) Program, have recognized the OVA1 (Multivariate Index Assay, MIA) test for its risk assessment outcomes.
“Support from either one of these renowned resources would have been meaningful, but having the combination of the support will allow us to build awareness and adoption of OVA1 even more quickly,” stated Valerie Palmieri, President and CEO of Vermillion. “We are on a mission to make sure every physician is aware of OVA1. Every day, 39 women die of ovarian cancer. Since launching OVA1, we have made a difference in the lives of over 103,000 patients with zero safety or efficacy issues. OVA1 is FDA cleared, endorsed by the American Congress of Obstetricians and Gynecologists (ACOG), and covered by Medicare nationwide, and Medicaid on a state-by-state basis. Our goal is to change the standard of care for managing both high-risk and low-risk pelvic mass patients, as 1 in 5 women have a pelvic mass in their lifetime. We have built a solid foundation and look forward to executing on our plan.”
In the UpToDate article entitled: “Serum biomarkers for evaluation of an adnexal mass for epithelial carcinoma of the ovary, fallopian tube, or peritoneum,” published in the March 2018 issue, authors Frederick Rand Ueland, MD and Andrew John Li, MD found that physicians using the OVA1 test in conjunction with the American College of Obstetricians and Gynecologists (ACOG) criteria identified more ovarian cancers than physicians using the ACOG criteria alone. UpToDate is an evidence-based physician-authored clinical decision support resource used by physicians to make point-of-care decisions and is read by over 1.3 million clinicians in more over 180 countries.
In a national Continuing Medical Education (CME) program, OVA1 is included as a risk assessment strategy in an activity entitled: “Adnexal Mass Management: Risk Stratification & Management Practice for Best Patient Outcomes.”
The CME program is available through Omnia Education’s website for CME credit (https://omniaeducation.com/programs/cme/). The video also is available from ASPiRA’s website (http://www.aspiralab.com).
About Vermillion, Inc.
Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. Vermillion, Inc.’s tests are intended to characterize and stage disease, and to help guide decisions regarding patient treatment, which may include decisions to refer patients to specialists, to perform additional testing, or to assist in monitoring response to therapy.
